Helicobacter Pylori Infection
No reduction in gastric cancer incidence, mortality by adding H. pylori screening to FIT
An invitation to screen for Helicobacter pylori along with fecal immunochemical testing did not significantly reduce gastric cancer incidence or mortality over approximately 5 years vs. FIT alone, according to a study conducted in Taiwan.
Vonoprazan-bismuth triple therapy eradicates H. pylori in up to 90.9% vs. standard care
A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with Helicobacter pylori infection, according to data.
Individuals with high genetic risk for gastric cancer may benefit from H. pylori treatment
Treatment for Helicobacter pylori infection was associated with reduced risk for gastric cancer among patients with a high genetic risk, suggesting that chemoprevention should be personalized to genetic risk, according to data.
FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals
In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.
FDA approves reformulated Voquezna Triple, Dual Pak for H. pylori infection
The FDA has approved the prior approval supplement for Phathom Pharmaceutical’s reformulated vonoprazan tablets for its Voquezna Triple Pak and Voquezna Dual Pak to treat adults with Helicobacter pylori infection, according to a company release.
FDA approves ‘more flexible Talicia regimen’ of three daily doses for H. pylori infection
The FDA approved the supplemental new drug application for Talicia for Helicobacter pylori eradication, shortening the current dosing regimen to improve patient adherence, according to manufacturer RedHill Biopharma.
H. pylori eradication varies widely across Africa; antibiotic susceptibility review needed
The eradication rate of Helicobacter pylori in Africa varied widely by country, duration of therapy and type of diagnostic test used, underscoring the need for optimized treatment regimens, according to a systemic review and meta-analysis.
Ibex receives CE mark for AI-powered solution for gastric cancer detection
FDA approves two vonoprazan treatment regimens for H. pylori infection
Phathom Pharmaceuticals Inc. has announced FDA approval for its Voquezna Triple and Dual Paks for the treatment of Helicobacter pylori infection in adults.
H. pylori infection: Resistance and recommendations for treatment
Helicobacter pylori is a spiral-shaped gram-negative rod that colonizes the gastric mucosa. H. pylori is mostly acquired in childhood before age 10 years, with more than 50% of people worldwide carrying the organism.